Compagnie Lombard Odier SCmA’s Centessa Pharmaceuticals CNTA Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,820	Closed	-$55.1K	–	518
2023 Q4	$46.3K	Hold	5,820	–	–	﹤0.01%	419
2023 Q3	$37.7K	Hold	5,820	–	–	﹤0.01%	443
2023 Q2	$36K	Hold	5,820	–	–	﹤0.01%	441
2023 Q1	$22.4K	Hold	5,820	–	–	﹤0.01%	510
2022 Q4	$19K	Hold	5,820	–	–	﹤0.01%	574
2022 Q3	$23K	Buy	+5,820	New	+$26.6K	﹤0.01%	523
2022 Q1	–	Sell	-5,820	Closed	-$66K	–	613
2021 Q4	$66K	Buy	5,820 +3,070	+112%	+$41.3K	﹤0.01%	480
2021 Q3	$46K	Buy	+2,750	New	+$56.9K	﹤0.01%	507

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Compagnie Lombard Odier SCmA's CNTA Position: Q1 2024 in Review

Compagnie Lombard Odier SCmA sold out of Centessa Pharmaceuticals (CNTA) in Q1 2024, closing a stake of 5,820 shares — an estimated $55.1K sold.

Compagnie Lombard Odier SCmA first reported a position in CNTA in Q3 2021 and held it in 8 quarters. The position peaked at $66K in Q4 2021. 69 funds tracked by Wall St. Rank hold CNTA as of Q1 2024.

Compagnie Lombard Odier SCmA reported no remaining Centessa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 5,820 Centessa Pharmaceuticals shares in Q1 2024, an estimated $55.1K.
Compagnie Lombard Odier SCmA first reported a position in Centessa Pharmaceuticals in Q3 2021 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's Centessa Pharmaceuticals position peaked at $66K in Q4 2021.
69 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2024.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2024, filed 1 May 2024.